6836 BEE CAVE ROAD, AUSTIN, TX
Savara Inc. Enters Lease Agreement for New Headquarters Location
Material disclosure
Investor Presentation
Material Contracts, Other Events
Announces $75M Royalty Funding Agreement To Support The Potential Launch Of MOLBREEVI In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), Investor Presentation
Shareholder votes
Savara Refused FDA Filing For Molbreevi* BLA in Autoimmune PAP Treatment
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence